RE:RE:RE:Q&A indicates LSA has brought some good new investorsJam-packed with good solid and well-explained and diagramed information. In the past, we've all commented how their data and articulation just wasn't enough to convince potential investors to take a look. Obviously POC hard data will really get people to look, but I have to say this should get a few intrigued with the possibility. It won't be huge, but they were very logical how they built up the novel scientific basis, their innovation and lead in the field, the importance of their target/linker and cleaveage and then showed convincingly the pre-clinical possibilities around it, described the trial very clearly and pushed the advantage of the FDA fast-track and what they may do for accellerating the first to market indication for them. I like how it kept building facts on top of each other and they were balanced about what they understand and what they do not and are investigating in a way that added a very high degree of credibility around this presentation.
Definitely an A from me!
qwerty22 wrote: I'm fore-seeing an "A" on the weekly report card, that was great. Very professional.
Wino115 wrote:
Or JFM Scarlet and QWERTY stuffed the Q&A box.
SPCEO1 wrote: Very scientific questions indicate to me that US based institutions are indeed on this call - a very good sign for LSA's capabilities.